IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Brad C. Dunlap who wrote (655)	4/17/1997 9:40:00 AM
From: PSC	of 1762

You mentioned "potential serious side effects from methotrexate". Methotrexate has up till recently been used almost exclusively by the oncology community, where it has been used in varying diseases for the last 35 years. Extensive information is available about pharmacokinetics, and long term side effects, and frankly, except in industrial strength doses as for those used in osteosarcoma, methotrexate when given judiciously DOES NOT cause long term, or even serious short term side effects. It's one of the least toxic drugs in the oncologist's armenmentarium. Methotrexate, has also been used for a few years in the treatment of severe RA, so it is reasonable to try new RA drugs both alone, in comparison with the state of the art therapy...e.g. methotrexate, or in combination. Not sure what the FDA would prefer. What's ML/MS? The drop to 18 yesterday took my breath away. This stock is not for the weak of heart!!

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next